Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Arrowhead Pharma ( NASDAQ:ARWR ) , Assembly Biosciences ( NASDAQ:ASMB )
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
The Zacks Analyst Blog Highlights MCOW, SCOW, SFLO and CALF
Pacer???s new MCOW and SCOW ETFs spotlight quality small- and mid-cap firms with strong free cash flow, joining rivals SFLO and CALF.
Looking for Quality ETFs in Smaller Caps? Tap 2 New FCF Aristocrats
MCOW and SCOW debut with quality-focused strategies, targeting mid- and small-cap stocks with strong free cash flow records.
Can Korlym Drive Corcept's Growth Through the Rest of 2025?
CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.
Should Invesco S&P SmallCap Momentum ETF ( XSMO ) Be on Your Investing Radar?
Style Box ETF report for ...
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Corcept Therapeutics ( CORT ) Tops Q2 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 5 years by 19.89% on an annualized basis producing an average annual return of 34.36%. Currently, Corcept Therapeutics has a market capitalization of $7.51 billion.
What's Driving the Market Sentiment Around Corcept Therapeutics? - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics's CORT short percent of float has fallen 9.51% since its last report. The company recently reported that it has 11.45 million shares sold short, which is 14.55% of all regular shares that are available for trading.
Madrigal ( MDGL ) Moves 10.9% Higher: Will This Strength Last?
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Here's How Much $100 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth Today - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return of 13.43%. Currently, Corcept Therapeutics has a market capitalization of $7.66 billion.
Should Invesco S&P SmallCap Momentum ETF ( XSMO ) Be on Your Investing Radar?
Style Box ETF report for ...
Aurinia ( AUPH ) Surges 7.5%: Is This an Indication of Further Gains?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF ( GSSC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Corcept Therapeutics ( NASDAQ:CORT )
It was reported on June 18, that Gary Charles Robb, Chief Business Officer at Corcept Therapeutics CORT executed a significant insider sell, according to an SEC filing. What Happened: Robb's recent Form 4 filing with the U.S.
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 20 years by 5.45% on an annualized basis producing an average annual return of 13.86%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF ( JPSE ) Be on Your Investing Radar?
Style Box ETF report for ...
Major Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $0 - Corcept Therapeutics ( NASDAQ:CORT )
Disclosed in a recent SEC filing on June 13, JR, Board Member at Corcept Therapeutics CORT, made a noteworthy transaction involving the exercise of company stock options. What Happened: Disclosed in a Form 4 filing on Friday with the U.S.
Is Invesco S&P SmallCap Quality ETF ( XSHQ ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF ( GSSC ) Be on Your Investing Radar?
Style Box ETF report for ...
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Corcept Therapeutics ( NASDAQ:CORT )
DAZALS trial missed its main goal, but patients on 300 mg dazucorilant had significantly improved survival at 24 weeks. ROSELLA trial met its endpoint, showing a 30% reduced risk of progression in ovarian cancer with relacorilant plus nab-paclitaxel.
Should Invesco S&P SmallCap Quality ETF ( XSHQ ) Be on Your Investing Radar?
Style Box ETF report for ...
Corcept ( CORT ) Down 1.7% Since Last Earnings Report: Can It Rebound?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an average annual return of 40.21%. Currently, Corcept Therapeutics has a market capitalization of $8.22 billion.
New Strong Sell Stocks for May 29th
CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 5 years by 23.49% on an annualized basis producing an average annual return of 38.6%. Currently, Corcept Therapeutics has a market capitalization of $7.63 billion.
How Do Investors Really Feel About Corcept Therapeutics? - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics's CORT short percent of float has fallen 25.63% since its last report. The company recently reported that it has 12.29 million shares sold short, which is 16.31% of all regular shares that are available for trading.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
Corcept Therapeutics ( CORT ) Meets Q1 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.
Heron Therapeutics ( HRTX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares Core S&P Small-Cap ETF ( IJR ) Be on Your Investing Radar?
Style Box ETF report for ...
Should Invesco S&P SmallCap Momentum ETF ( XSMO ) Be on Your Investing Radar?
Style Box ETF report for ...
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion.
Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF ( GSSC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should iShares S&P Small-Cap 600 Growth ETF ( IJT ) Be on Your Investing Radar?
Style Box ETF report for ...
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Corcept Therapeutics ( NASDAQ:CORT )
Corcept Therapeutics CORT has outperformed the market over the past 20 years by 7.21% on an annualized basis producing an average annual return of 15.13%. Currently, Corcept Therapeutics has a market capitalization of $7.34 billion.
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week ( Mar 31-Apr 4 ) - Celsius Holdings ( NASDAQ:CELH ) , Corcept Therapeutics ( NASDAQ:CORT ) , PVH ( NYSE:PVH )
Corcept Therapeutics surged 36.28% after a successful Phase 3 trial for ovarian cancer treatment. Mr. Cooper Group stock jumped 28.44% on news of a $9.4B all-stock acquisition by Rocket Companies. Feel unsure about the market's next move?
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
CORT and AXSM are in the spotlight this week following the announcement of study data.
Does Corcept ( CORT ) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Corcept Therapeutics Unusual Options Activity For April 01 - Corcept Therapeutics ( NASDAQ:CORT )
Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
